Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation

Archives of Internal Medicine

Volumn 160, Issue 11, 2000, Pages 1612-1617

  Hylek, Elaine M ^a   Chang, YuChiao ^a   Skates, Steven J ^a   Hughes, Robert A ^a   Singer, Daniel E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PHYTOMENADIONE; WARFARIN;

ADULT; AGED; AMBULATORY CARE; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERNATIONAL STANDARD UNIT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOEMBOLISM;

EID: 0034641072     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.160.11.1612     Document Type: Article

References (20)

1. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1998;114 (suppl):445S-469S.
2. Glover JJ, Morrill GB. Conservative treatment of overanticoagulated patients. Chest. 1995;108:987-990.
3. Lousberg TR, Witt DM, Beall DG, Carter BL, Malone DC. Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med. 1998;158:528-534.
4. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med. 1989;87:144-152.
5. The Stroke Prevention in Atrial Fibrillation Investigators. Bleeding during antithrombotic therapy in patients with atrial fibrillation. Arch Intern Med. 1996;156: 409-416.
6. Palareti G, Leali N, Coccheri S, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study. Lancet. 1996; 348:423-428.
7. van der Meer FJM, Rosendaal FR, Vandenbroucke JP, Briet E. Bleeding complications in oral anticoagulant therapy: an analysis of risk factors. Arch Intern Med. 1993;153:1557-1562.
8. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
9. Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998;79:657-662.
10. Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest. 1995; 108(suppl):231S-246S.
11. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic Research: Principles and Quantitative Methods. Belmont, Calif: Lifetime Learning; 1982:299.
12. Vollset SE. Confidence intervals for a binomial proportion. Stat Med. 1993;12: 809-824.
13. Rosner B. Fundamentals of Biostatistics. Belmont, Calif: Wadsworth Publishing Co; 1995;609-621.
14. Notari RE. Biopharmaceutics and Clinical Pharmacokinetics. 4th ed. New York, NY: Marcel Dekker lnc; 1987:7.
15. White RH, McKittrick T, Hutchinson R, Twitchell J. Temporary discontinuation of warfarin therapy: changes in the international normalized ratio. Ann Intern Med. 1995;122:40-42.
16. Petitti D, Strom B, Melmon K. Duration of warfarin anticoagulant therapy and the probabilities of recurrent thromboembolism or hemorrhage. Am J Med. 1986; 81:255-259.
17. Finn SD, McDonell M, Martin D, et al. Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med. 1993;118:511-520.
18. Weibert R, Le DT, Kayser SR, Rapaport Sl. Correction of excessive anticoagulation with low-dose oral vitamin K. Ann Intern Med. 1997;126:959-962.
19. Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J. Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost. 1998;79:1116-1118.
20. Pengo V, Banzato A, Garelli E, et al. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K) compared with warfarin discontinuation. Blood Coagul Fibrinolysis. 1993;4:739-741.